Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Akebia Therapeutics, Inc. (AKBA)
|
|
| Income Statement |
|
|
|
| Standardized | As Reported |
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-23 | Mar-31-23 | Dec-31-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 | Jun-30-21 |
| | 8-K | 10-Q | 8-K | 10-Q | 10-Q | 10-K | 10-Q | 10-Q |
| Revenues [+] | 56.4 | 40.1 | 55.2 | 126.8 | 61.7 | 59.6 | 48.8 | 52.9 |
| Products | 42.2 | | 49.7 | | | | | |
| Revenue growth | -55.5% | -35.0% | -7.4% | 139.6% | 18.0% | 5.1% | -18.7% | -41.3% |
| Cost of goods sold [+] | 17.3 | 19.5 | -3.1 | 18.6 | 31.3 | 50.4 | 15.9 | 52.5 |
| Amortization of intangibles | | 9.0 | | 9.0 | 9.0 | 9.0 | 9.0 | 9.0 |
| Gross profit | 39.1 | 20.6 | 58.3 | 108.2 | 30.4 | 9.3 | 32.8 | 0.4 |
| Gross margin | 69.3% | 51.4% | 105.6% | 85.3% | 49.2% | 15.5% | 67.3% | 0.8% |
| Selling, general and administrative [+] | 27.0 | 25.2 | 30.6 | 32.8 | 44.3 | 44.8 | 46.4 | 41.7 |
| General and administrative | | | | | | 44.8 | | |
| Other selling, general and administrative | | | | | | | | |
| Research and development | 20.2 | 19.7 | 31.9 | 26.0 | 43.8 | 29.6 | 40.5 | 37.2 |
| Other operating expenses | -8.1 | 0.6 | 0.9 | 0.9 | 0.7 | 1.0 | 0.9 | 0.9 |
| EBITDA [+] | -0.1 | -15.4 | | 57.9 | -49.1 | -56.7 | -45.4 | -69.8 |
| EBITDA growth | -100.1% | -68.6% | -91.0% | -182.9% | -11.5% | -27.0% | -11.8% | 43.5% |
| EBITDA margin | -0.1% | -38.4% | -9.3% | 45.6% | -79.5% | -95.1% | -93.1% | -132.0% |
| Depreciation | | 0.4 | | 0.4 | 0.4 | 0.4 | 0.5 | 0.5 |
| EBITA | -0.1 | -15.8 | -5.1 | 57.4 | -49.5 | -57.1 | -45.9 | -70.3 |
| EBITA margin | -0.1% | -39.4% | -9.3% | 45.3% | -80.2% | -95.9% | -94.1% | -132.9% |
| Amortization of intangibles | 9.0 | 9.0 | | 9.0 | 9.0 | 9.0 | 9.0 | 9.0 |
| EBIT [+] | -9.1 | -24.8 | -5.1 | 48.4 | -58.5 | -66.2 | -54.9 | -79.3 |
| EBIT growth | -118.8% | -57.5% | -92.2% | -161.0% | -9.9% | -22.5% | -5.5% | 36.1% |
| EBIT margin | -16.1% | -61.9% | -9.3% | 38.2% | -94.8% | -111.0% | -112.6% | -149.9% |
| Non-recurring items | -0.1 | 0.1 | 1.2 | 14.5 | | | | |
| Interest expense | | 1.6 | | 5.0 | 5.1 | 5.1 | 5.1 | 5.0 |
| Interest expense | | 1.6 | | 5.0 | 5.1 | 5.1 | 5.1 | 5.0 |
| Other income (expense), net [+] | -2.2 | 0.3 | -1.2 | 0.4 | 1.1 | 0.6 | 0.4 | 1.3 |
| Other | | 0.3 | | 0.4 | 1.1 | 0.6 | 0.4 | 1.3 |
| Pre-tax income | -11.2 | -26.2 | -7.6 | 29.3 | -62.4 | -70.7 | -59.5 | -83.0 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -11.2 | -26.2 | -7.6 | 29.3 | -62.4 | -70.7 | -59.5 | -83.0 |
| Net margin | -19.8% | -65.3% | -13.7% | 23.1% | -101.2% | -118.6% | -122.1% | -156.9% |
| |
| Basic EPS [+] | ($0.06) | ($0.14) | ($0.04) | $0.16 | ($0.35) | ($0.43) | ($0.34) | ($0.51) |
| Growth | -137.5% | -59.2% | -90.4% | -131.0% | -23.2% | -32.2% | -18.1% | -59.9% |
| Diluted EPS [+] | ($0.06) | ($0.14) | ($0.04) | $0.15 | ($0.35) | ($0.43) | ($0.34) | ($0.51) |
| Growth | -138.9% | -59.2% | -90.4% | -129.9% | -23.2% | -32.2% | -18.1% | -59.9% |
| |
| Shares outstanding (basic) [+] | 186.8 | 184.8 | 184.0 | 183.6 | 179.6 | 165.9 | 173.8 | 161.3 |
| Growth | 1.8% | 2.9% | 10.9% | 13.8% | 16.8% | 19.9% | 21.3% | 17.8% |
| Shares outstanding (diluted) [+] | 186.8 | 184.8 | 184.0 | 190.4 | 179.6 | 165.9 | 173.8 | 161.3 |
| Growth | -1.9% | 2.9% | 10.9% | 18.0% | 16.8% | 19.9% | 21.3% | 17.8% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|